Overview

Open Label Safety Study in Acute Treatment of Migraine

Status:
Completed
Trial end date:
2019-07-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceuticals, Inc.